Accord Biopharm Patent-Cliff Exposure & CMS Drug Spending Portfolio

Accord Biopharm (US): 2 reconciled FDA prescription therapies, $1.4M 2024 CMS Part D & Medicaid spend, and $4,270 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$1.4M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$1.4M
California HCAI SB 17 FilingsSpecialty launch notice ($4,270 intro WAC)